Trump signs memo to crack down on direct-to-consumer pharma ads
The Trump administration issued about 100 enforcement letters targeting misleading pharmaceutical ads and plans to close a 1997 loophole allowing omission of side effects disclosures.
- President Donald Trump signed an executive memorandum ordering action on misleading direct-to-consumer drug advertising to ensure transparency and accuracy in ads.
- President Donald Trump signed a memorandum directing the Department of Health and Human Services to ensure transparency and accuracy in direct-to-consumer drug advertising.
36 Articles
36 Articles
Trump admin announces crackdown on pharmaceutical ads run on TV, social media in US; check details
The new memorandum directs the federal health agencies to require pharmaceutical companies to disclose more side effects in their ads and enforce existing rules about misleading ads more strictly.

Trump Mandates Transparency in Drug Advertising
President Donald Trump signed an executive memorandum on Tuesday ordering his administration to address misleading direct-to-consumer (DTC) drug advertising and to ensure "transparency and accuracy." In the memo, Trump instructed the Department of Health and Human Services to take "appropriate action" on regulation surrounding drug advertising, including more disclosures about side effects. "The FDA has historically stipulated that a manufacture…
Coverage Details
Bias Distribution
- 41% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium